RAF1 and hepatocellular carcinoma: It can prolong the survival time of HCC patients by inhibiting cell proliferation and angiogenesis and promoting cell apoptosis through inhibiting a variety of intracellular and cell surface kinases (such as c-raf, BRAF, and RET), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) [38, 39].